Page last updated: 2024-12-05

deoxyribose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID5460005
CHEBI ID28816
SCHEMBL ID37362
MeSH IDM0006018

Synonyms (53)

Synonym
lsw4h01241 ,
unii-lsw4h01241
4-01-00-04181 (beilstein handbook reference)
aldehydo-2-deoxy-d-ribose
CHEBI:28816 ,
d-drib
einecs 208-573-0
brn 1721978
2-deoxyribose ,
ai3-52228
2-deoxy-d-erythro-pentose
2-deoxy-d-ribose ,
thyminose
533-67-5
deoxyribose
2-deoxy-d-ribose, suitable for cell culture, bioreagent
2-deoxy-d-ribose, 97%
2-deoxy-d-ribose, >=99.0% (tlc)
AB7E0364-402C-426E-A57E-D04E9906FC52
(3s,4r)-3,4,5-trihydroxypentanal
d-(-)-2-deoxyribose
(2s,4s,5r)-5-(hydroxymethyl)oxolane-2,4-diol
A829544
arabinose, 2-deoxy-
dl-2-deoxyribose
einecs 217-028-6
1724-14-7
2-deoxy-erythro-pentose
d-erythro-2-deoxypentose
2-deoxy-d-erythropentose
AM20100306
EPITOPE ID:149165
Z-1006
cladribine impurity e [ep impurity]
2-deoxyribose, d-
d-2-deoxyribose [mi]
S3101
SCHEMBL37362
ASJSAQIRZKANQN-CRCLSJGQSA-N
AKOS016842272
mfcd00135904
GS-3029
CS-M3535
DTXSID70883428
HY-77956
Q27887395
DTXSID701015730
2-deoxy-dl-ribose
EN300-106817
aldehydo-thyminose
nsc772796
nsc-772796
Z1255395325

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Furthermore, the hydroxyl radical scavengers mannitol and 2-deoxyribose inhibited Fe2/TBH-mediated lipid peroxidation, but not cell killing, suggesting that hydroxyl radical may not be involved in the critical toxic event."( Evaluation of iron binding and peroxide-mediated toxicity in rat hepatocytes.
Bannenberg, GL; Moldéus, P; Shertzer, HG, 1992
)
0.28
"There is a growing body of experimental and clinical evidence to suggest that oral or rectal administration of 5-ASA or 5-ASA conjugates is associated with significant adverse side effects including pancreatitis, hepatitis, and renal toxicity."( Prooxidant properties of 5-aminosalicylic acid. Possible mechanism for its adverse side effects.
Grisham, MB; Marshall, S; Sandhu, IS; Ware, K; Yamada, T, 1992
)
0.28

Compound-Compound Interactions

ExcerptReferenceRelevance
" The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19."( 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection.
Ahmad, SI, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" The latter requirement confers extremely high lipophilicities on these compounds, unknown amongst chemotherapeutic nucleosides, which may be of considerable importance in formulation, dosing and tissue distribution."( Furano pyrimidines as novel potent and selective anti-VZV agents.
Andrei, G; Balzarini, J; Barucki, H; Bidet, O; Blewett, S; Brancale, A; Carangio, A; De Clercq, E; Jarvis, C; Jones, G; Jukes, A; Luoni, G; McGuigan, C; Pathirana, R; Snoeck, R; Srinivasan, S, 2001
)
0.31
" Administration of estradiol pellets (0-200 microg) to ovariectomized rats increased mammary epithelial cell proliferation, according to a dose-response relationship up to the 100 microg dose."( Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA.
Antelo, F; Cesar, D; Christiansen, M; Chu, A; Hellerstein, MK; Hoh, R; Kim, J; McCune, JM; Misell, LM; Neese, RA; Strawford, A; Turner, S, 2002
)
0.31
" Using a benzylhydroxylamine dioxime derivative of [2H4]-labeled cis-1,4-dioxo-2-butene as an internal standard, the dose-response for the formation of 5'-(2-phosphoryl-1,4-dioxobutane) was determined to be linear for gamma-radiation, with approximately 6 lesions per 10(6) nt per Gy, and nonlinear for Fe2+-EDTA."( 5'-(2-phosphoryl-1,4-dioxobutane) as a product of 5'-oxidation of deoxyribose in DNA: elimination as trans-1,4-dioxo-2-butene and approaches to analysis.
Bohnert, T; Chen, B; Dedon, PC; Zhou, X, 2004
)
0.32
" Cells treated with neocarzinostatin showed a clear dose-response relationship for the formation of N(6)-formyl-lysine, with this nucleosome linker-selective DNA-cleaving agent causing selective N(6)-formylation of the linker histone H1."( N-formylation of lysine in histone proteins as a secondary modification arising from oxidative DNA damage.
Dedon, PC; Dong, M; Jiang, T; Taghizadeh, K; Zhou, X, 2007
)
0.34
" The yields were determined and the dose-response curves explained by a mechanistic model consisting of three reaction pathways: (1) trappable-radical single-track, (2) trappable-radical multiple-track, and (3) molecular."( Mechanisms of direct radiation damage in DNA, based on a study of the yields of base damage, deoxyribose damage, and trapped radicals in d(GCACGCGTGC)(2).
Bernhard, WA; Gilbert, DC; Naumenko, KA; Purkayastha, S; Razskazovskiy, Y; Sharma, KK; Swarts, SG, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
deoxypentose
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (943)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990251 (26.62)18.7374
1990's232 (24.60)18.2507
2000's294 (31.18)29.6817
2010's140 (14.85)24.3611
2020's26 (2.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews37 (3.74%)6.00%
Case Studies3 (0.30%)4.05%
Observational0 (0.00%)0.25%
Other950 (95.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]